Amarin (AMRN) Trading Down 6%

Amarin Co. (NASDAQ:AMRN)’s share price traded down 6% during mid-day trading on Thursday . The company traded as low as $2.98 and last traded at $2.99. 4,355,551 shares were traded during mid-day trading, an increase of 109% from the average session volume of 2,085,432 shares. The stock had previously closed at $3.18.

A number of equities analysts recently issued reports on the stock. Cantor Fitzgerald set a $10.00 price target on shares of Amarin and gave the stock a “buy” rating in a research note on Thursday, January 4th. BidaskClub upgraded shares of Amarin from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Zacks Investment Research upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. Finally, ValuEngine upgraded shares of Amarin from a “sell” rating to a “hold” rating in a research note on Wednesday, December 20th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Amarin presently has an average rating of “Hold” and an average target price of $7.75.

How to Become a New Pot Stock Millionaire

The company has a current ratio of 1.41, a quick ratio of 1.13 and a debt-to-equity ratio of -1.12. The company has a market cap of $914.96, a PE ratio of -11.96 and a beta of 0.72.



Amarin (NASDAQ:AMRN) last posted its earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). The business had revenue of $53.87 million for the quarter, compared to analyst estimates of $52.73 million. The business’s revenue for the quarter was up 39.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) EPS. equities analysts forecast that Amarin Co. will post -0.33 earnings per share for the current year.

In other Amarin news, insider Steven B. Ketchum sold 135,205 shares of the company’s stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $4.41, for a total transaction of $596,254.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, General Counsel Joseph T. Kennedy sold 44,857 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $3.73, for a total transaction of $167,316.61. The disclosure for this sale can be found here. Insiders have sold a total of 207,004 shares of company stock worth $841,702 in the last 90 days. Company insiders own 3.72% of the company’s stock.

Several large investors have recently modified their holdings of the company. State Street Corp lifted its stake in shares of Amarin by 1.3% in the 2nd quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock worth $814,000 after purchasing an additional 2,640 shares during the period. LPL Financial LLC lifted its stake in shares of Amarin by 12.3% in the 4th quarter. LPL Financial LLC now owns 143,642 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 15,782 shares during the period. Paloma Partners Management Co bought a new position in shares of Amarin in the 4th quarter worth approximately $141,000. Hoylecohen LLC bought a new position in shares of Amarin in the 4th quarter worth approximately $142,000. Finally, Geode Capital Management LLC lifted its stake in shares of Amarin by 32.7% in the 4th quarter. Geode Capital Management LLC now owns 241,576 shares of the biopharmaceutical company’s stock worth $968,000 after purchasing an additional 59,576 shares during the period. Hedge funds and other institutional investors own 38.16% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Amarin (AMRN) Trading Down 6%” was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://stocknewstimes.com/2018/04/19/amarin-amrn-trading-down-6.html.

Amarin Company Profile

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply